Organon & Co | OGN - Ebit


Organon & Co reported $377M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
Bristol-Myers Squibb USD 255M 44M Sep/2026
Celltrion KRW 20.08B 6.67B Jun/2026
Cspc Pharmaceutical CNY 206.26M 1.02B Dec/2025
Deva Holding AS TRY 820.88M 192.13M Sep/2023
Dianthus Therapeutics USD -61.48M 14.95M Jun/2026
Divis Laboratories Ltd INR 11.29B 3.15B Jun/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Glaxosmithkline GBP 2.15B 157M Sep/2026
Kangmei Pharma CNY -35.26M 22.54M Jun/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Laboratorios Farma EUR 135.05M 49.84M Dec/2023
Malin Corporation EUR -1.1M 300K Dec/2024
Medical Developments International AUD -36K 12.96M Dec/2025
Merck USD 7.33B 6.49B Sep/2026
Neuren Pharmaceuticals AUD 17.01M 154.09M Dec/2025
Novartis USD 1.78B 2.4B Sep/2026
Organigram Holdings CAD 5.33M 15.12M Jun/2026
Organon & Co USD 377M 86M Sep/2026
Ovoca Bio EUR -173K 990K Dec/2025
Pharma Mar EUR 7.65M 9.06M Sep/2026
Qiagen NV USD 141.4M 44.52M Jun/2026
Sartorius EUR 179.8M 15.8M Sep/2026
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Tilray USD -20.01M 9.34M Sep/2025
Zealand Pharma A/S -389M 318.05M Mar/2026